Banzel Mobile Logo A Challenging Form of Epilepsy Seizure Types in LGS LGS Patient Profiles Pivotal Trial Design Efficacy of BANZEL® in Seizure Reduction Seizure Severity Rating Responder Rates Adverse Reactions Mechanism of Action/Pharmacokinetics Dosing

BANZEL is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in pediatric patients 1 year of age and older, and in adults.

Prescribing Information Important Safety Information For Patients

Error, please try again.

Return to Home page.

Efficacy icon

EFFICACY ►

Learn about the efficacy of BANZEL® (rufinamide) in the pivotal trial